CEBP Meeting Calendar Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smedby, K. E.
Right arrow Articles by Askling, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smedby, K. E.
Right arrow Articles by Askling, J.
Related Collections
Right arrow Epidemiology and Prevention
Right arrow Epidemiology and Prevention: Genetics and Biomarkers
Cancer Epidemiology Biomarkers & Prevention Vol. 15, 2069-2077, November 2006
© 2006 American Association for Cancer Research

Review

Malignant Lymphomas in Autoimmunity and Inflammation: A Review of Risks, Risk Factors, and Lymphoma Characteristics

Karin Ekström Smedby1, Eva Baecklund3 and Johan Askling2

1 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet; 2 Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Hospital, Stockholm, Sweden; and 3 Department of Rheumatology, Akademiska Hospital, Uppsala, Sweden

Requests for reprints: Karin Ekström Smedby, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, S-171 77 Stockholm, Sweden. Phone: 59122771580; Fax: 59122434926. E-mail: karin.ekstrom{at}meb.ki.se


   Abstract
Top
 Abstract
Introduction
 Methodologic Issues
 Malignant Lymphomas
 Autoimmune/Inflammatory...
 Common Mechanisms of...
 Clinical Aspects
 Conclusions
 References
 
Certain autoimmune and chronic inflammatory conditions, such as Sjögren's syndrome and rheumatoid arthritis (RA), have consistently been associated with an increased risk of malignant lymphomas, but it is unclear whether elevated lymphoma risk is a phenomenon that accompanies inflammatory conditions in general. Likewise, it is debated whether the increased risk identified in association with some disorders pertains equally to all individuals or whether it varies among groups of patients with different phenotypic or treatment-related characteristics. It is similarly unclear to what extent the increased lymphoma occurrence is mediated through specific lymphoma subtypes. This update reviews the many findings on risks, risk levels, and lymphoma characteristics that have been presented recently in relation to a broad range of chronic inflammatory, including autoimmune, conditions. Recent results clearly indicate an association between severity of chronic inflammation and lymphoma risk in RA and Sjögren's syndrome. Thus, the average risk of lymphoma in RA may be composed of a markedly increased risk in those with most severe disease and little or no increase in those with mild or moderate disease. The roles of immunosuppressive therapy and EBV infection seem to be limited. Furthermore, RA, Sjögren's syndrome, systemic lupus erythematosus, and possibly celiac disease may share an association with risk of diffuse large B-cell lymphoma, in addition to well-established links of Sjögren's syndrome with risk of mucosa-associated lymphoid tissue lymphoma and of celiac disease with risk of small intestinal lymphoma. However, there is also obvious heterogeneity in risk and risk mediators among different inflammatory diseases. (Cancer Epidemiol Biomarkers Prev 2006;15(11):2069–77)


   Introduction
Top
 Abstract
 Introduction
Methodologic Issues
 Malignant Lymphomas
 Autoimmune/Inflammatory...
 Common Mechanisms of...
 Clinical Aspects
 Conclusions
 References
 
Over recent decades, the worldwide incidence of malignant lymphomas has increased dramatically (1). In the United States, non-Hodgkin lymphoma (NHL) is now the fifth most commonly diagnosed malignancy (2). The causes of most new cases of lymphoma are poorly understood, as reflected by the relatively few risk factors that have been established (1). Over the years, several studies have linked certain autoimmune and chronic inflammatory conditions, including rheumatoid arthritis (RA), Sjögren's syndrome, systemic lupus erythematosus (SLE), celiac disease, dermatitis herpetiformis, and chronic thyroiditis to an increased occurrence of lymphoma (3). However, the magnitude of the average lymphoma risk increase in each disorder varies considerably among studies (4). About the exposure, it is unclear whether the increased risk pertains equally to all individuals or varies among groups of patients with different phenotypic or treatment-related disease characteristics, which in turn remain to be defined. About the outcome, it is unclear to what extent the increased lymphoma occurrence is mediated through specific subtypes and whether the relevant subtypes vary among different inflammatory conditions. Another important question is whether elevated lymphoma risk accompanies states of chronic inflammation in general or whether it is specifically linked only to some disorders.

Revealing the nature of lymphomagenesis in relation to autoimmunity/inflammation is important from several points of view. Clinically, we need to learn how to identify individuals who are at substantially increased lymphoma risk and how optimally to intervene against this risk. In particular, we need to understand whether lymphomas arise as a consequence of medical treatment or because of a lack thereof. Considerable clinical concern about the potential lymphomagenicity of the recently introduced immunomodulatory treatments for chronic inflammatory diseases (5, 6) underscores the need for quantification of lymphoma risk based on patient characteristics, especially among patients channeled into treatment with these new drugs. Biologically, although lymphomas complicating defined autoimmune/inflammatory disorders comprise a minority of all lymphomas in the general population, any insights into the nature of this association may shed light on biological pathways of importance that also apply to hitherto unexplained "sporadic" lymphomas.

In this update, we summarize the current knowledge on risks, etiologic and clinical risk factors, and lymphoma subtypes in autoimmunity/inflammation. Importantly and in contrast to previous reviews of selected rheumatologic conditions (4, 7, 8), our update covers inflammation in a broader perspective.


   Methodologic Issues
Top
 Abstract
 Introduction
 Methodologic Issues
Malignant Lymphomas
 Autoimmune/Inflammatory...
 Common Mechanisms of...
 Clinical Aspects
 Conclusions
 References
 
Studies of lymphoma risk in autoimmune/inflammatory disorders are challenging for several reasons. First, autoimmune disorders and lymphoproliferative malignancies are both rare in the population, and large patient groups and long observation periods are therefore needed to observe meaningful associations between these disease groups. Registry-based cohort studies, typically based on hospital discharge diagnosis records, may overselect patients with severe disease. Such selection may limit the generalizibility of the findings and also obscure the duration of the latency period between the "onset" of the inflammatory disease and cancer development. Although registry-based cohort studies may have adequate statistical power, they seldom provide the opportunity to examine potential confounding factors and effect modifiers. There is also often a lack of detail about the outcome (e.g., lymphoma subtypes by histology or age group). Although case-control studies may offer better information about lymphoma subtypes and covariate exposures of interest, analyses may instead be hampered by low power, control selection bias, and/or differential recall between cases and controls. Population-based registries of incident cases and nested case-control studies in defined cohorts provide the best opportunities for prospective follow-up and assessment of relevant data.

Another complicating factor is the close relationship between chronic activation or dysregulation of the immune system and malignant transformation of the same immune cells, resulting in potential bias due to reversed causality (that is, incipient lymphomas causing paramalignant inflammation misclassified as, for example, RA; ref. 9). Many studies have noted a more pronounced lymphoma risk during the first year of follow-up after autoimmune/inflammatory disease diagnosis or have excluded the first follow-up period, indicating both presence and awareness of this problem.

For this update, we identified all published epidemiologic studies of cohort or case-control design, or case series, through Medline searches using combinations of the following key words: "[the disease in question]," "lymphoma," "cancer" or "malignancy," and "risk," "cohort," or "case-control." Rather than doing a formal meta-analysis of all studies encountered, we have summarized the results of the most important studies, with a focus on recent advances. Because of the large number of inflammatory conditions and studies identified through our search, articles cited were prioritized based on the following methodologic characteristics: largest study samples for the condition in question, population-based design, recent publication, or novel finding. Validity was further evaluated based on a well-defined study base, especially for case series.


   Malignant Lymphomas
Top
 Abstract
 Introduction
 Methodologic Issues
 Malignant Lymphomas
Autoimmune/Inflammatory...
 Common Mechanisms of...
 Clinical Aspects
 Conclusions
 References
 
Malignant lymphomas entail considerable heterogeneity with regard to morphologic and molecular characteristics as well as clinical course (10). In addition, there is growing evidence of etiologic variation among lymphoma subtypes (1). The two main types traditionally considered are NHL, which comprises ~90% of all cases, and Hodgkin lymphoma (HL), which accounts for the remaining 10%. Mature B-cell neoplasms comprise >85% of all NHL, and T-cell tumors comprise ~12% worldwide (10). The current WHO classification further distinguishes among close to 40 NHL subtypes (10), including chronic lymphocytic leukemia and plasma cell malignancies, and at least two distinct HL entities (the rare nodular lymphocyte predominant type and the larger group of classic HL further divided in four subcategories).

Worldwide, NHL constitutes the 10th most commonly diagnosed malignancy, whereas in the developed world it ranks 7th. The most common NHL subtypes in western countries are diffuse large B-cell lymphoma (~30% of cases) and follicular lymphoma (~20%). All other NHL subtypes have a frequency of <10% (10). During the second half of the 20th century, there was a dramatic increase in NHL incidence worldwide, of about 2% to 4% annually (1). However, in the beginning of the 1990s, the overall increase in incidence began to level off in most populations. The overall age-adjusted incidence of HL has been stable or slightly declining during the same period (11).

Well-established risk factors for lymphoma include uncommon disorders of strong immune perturbation, such as inherited disorders of immune dysfunction, HIV/AIDS, and organ transplantation. Pathogenic mechanisms in the context of immune dysfunction involve suppression or dysregulation of T-cell function, allowing for rapid EBV-driven B-cell proliferation, which results in a high proportion of EBV-positive lymphomas. Other established risk factors include certain infectious agents, a degree of familial aggregation, and some autoimmune disorders (1). Neither confirmed risk factors nor diagnostic improvements or classification changes can, however, fully explain the observed increase in NHL incidence over the past decades (12).


   Autoimmune/Inflammatory Conditions Linked to Lymphoma
Top
 Abstract
 Introduction
 Methodologic Issues
 Malignant Lymphomas
 Autoimmune/Inflammatory...
Common Mechanisms of...
 Clinical Aspects
 Conclusions
 References
 
Rheumatoid Arthritis
Several cohort studies (13-20) and a few case-control studies (21-23) showed increased risks of both NHL and HL in association with RA, with relative risks (RR) typically in the range of 1.5 to 4 (Table 1 ) regardless of study size or design. Cohort studies that identified prevalent RA patients based on hospitalization (14-17) may have yielded exaggerated RR estimates, as subjects with severe and long-lasting disease may have been overrepresented. However, more recent cohorts of incident RA patients followed from disease onset also reported an ~2-fold increase in risk (19, 20). Higher risk has often been noted in males compared with females (13-16, 18), but this difference was statistically significant only in the hitherto largest cohort study (17).


View this table:
[in this window]
[in a new window]
  		Table 1. Summary of autoimmune/inflammatory disorders consistently associated with risk of malignant lymphomas, including reported RR range, disease-related risk factors, associated lymphoma subtypes, and future research issues

 
The approximately doubled lymphoma risk in RA may encompass considerable heterogeneity in risk among subsets of patients. For instance, reports suggest that patients with Felty's syndrome (splenomegaly and granulocytopenia linked to severe, long-standing seropositive RA) are at a more markedly (5- to 10-fold) increased risk (17, 24). In addition, in two recent case-control studies of ~400 RA-associated lymphomas nested in a large, population-based RA cohort, various markers of disease severity (including joint destruction, erythrocyte sedimentation rates, number of affected joints, and cumulated inflammatory load) emerged as independent and strong risk factors (25, 26), with 3- to 10-fold increases in risk across rising levels of each such exposure. Indeed, the emerging pattern in RA thus suggests that the observed doubling of lymphoma risk may result from the conflation of a more pronounced RR in patients with the most severe disease (25, 26) and little or no increase in those with mild to moderate disease (23).

An alternative explanation for the association between RA and lymphoma risk is the existence of shared genetic and/or environmental risk factors for both conditions. However, in a registry-based cohort study of lymphoma risk in family members of RA patients, parents and siblings were at no or only a marginally increased risk of lymphoma, suggesting that much of the increased lymphoma risk in RA patients is due to factors directly related to the disease or its treatment (17).

Treatment of RA with disease-modifying antirheumatic drugs, including methotrexate, azathioprine, and other immunosuppressive substances, has been repeatedly suggested as a risk factor for RA-associated lymphomas (27-29). Many studies of disease-modifying antirheumatic drugs, however, did not take into account the close correlation between disease severity and propensity for antirheumatic treatments. More recent studies with detailed information on markers of inflammatory activity as well as treatment (18, 25, 26, 30) did not substantiate the proposed treatment-related increase in lymphoma risk, with the possible exception of azathioprine (26). Numerous case reports describe lymphoproliferative lesions arising during methotrexate therapy (10). These lymphoproliferations are often EBV positive (about 30-50%; refs. 31, 32) and may regress with methotrexate cessation (31, 33). However, there is little evidence that methotrexate per se (as used to treat inflammatory disorders) increases lymphoma risk (18, 26, 32). In a recent nested case-control study from our group, only 4 of 378 RA-associated lymphomas displayed spontaneous regression, and only 1 of these 4 occurred in a patient exposed to methotrexate (26).

With respect to other anti-inflammatory treatments, such as nonsteroidal anti-inflammatory drugs and systemic corticosteroids, an excess risk of lymphomas has been reported (22, 34-36). As with studies of disease-modifying antirheumatic drugs, most of these investigations are limited by the potential for confounding by indication, as they did not consider the effect of underlying diseases or reasons for treatment (22, 34, 36). In addition, several cohort and case-control studies showed no or inverse associations between use of nonsteroidal anti-inflammatory drugs (22, 26, 37-39), steroids (26, 34, 39, 40), or proxies thereof (41) and lymphoma risk. Thus, current evidence for a role of these medication groups in RA-associated lymphomagenesis is weak. With respect to treatment with tumor necrosis factor (TNF) antagonists, a conspicuous number of lymphomas were observed in the early trials of these drugs (5, 6, 42). These reports also suggested the existence of lymphomas with short latency and exceedingly poor prognosis and of fatal relapses in individuals with a pretreatment history of lymphoma in remission. Although increased risk was also reported in observational cohorts in postmarketing surveillance programs (43), larger cohort studies have thus far not confirmed any treatment-related excess of lymphoma in general (18, 19). Nonetheless, it is still premature to make firm conclusions about the true lymphoma risk in patients treated with TNF antagonists, as available observational studies have included only moderate numbers, not been able to adjust fully for RA disease activity, and not assessed long-term risk or the clinical course of the occurring lymphomas (18, 19).

With regard to NHL subtypes in RA, an increased proportion of diffuse large B-cell lymphoma was described in three of four studies (23, 32, 44, 45). In our recent nested case-control study of 378 RA-associated lymphomas, we noted not only a higher than expected proportion of this subtype but also a much stronger association of RA disease severity with diffuse large B-cell lymphoma (a 100-fold risk in those with highest compared with lowest global disease activity) than with other lymphoma types (around a 5-fold increase in risk; ref. 26). In a recent population-based case-control study with >3,000 NHL cases (23), we also observed a stronger association with diffuse large B-cell lymphoma in cases reporting severe RA disease than in those with mild disease. In addition, associations of RA with HL risk are typically more pronounced than those with NHL risk (13-17). However, the HL risk in existing studies on this topic (13-17) is likely inflated by a degree of misclassification of NHL as HL, a common problem in the past (46). Thus, the true risk increase of HL in RA remains uncertain. It is also unknown whether RA is associated with any particular subtype of HL by age group, histology, or EBV status, as no studies have determined RR of HL by subtype, most likely due to low statistical power. However, in the large nested case-control study of RA-associated lymphomas (26), the distribution of HL cases according to histologic subtype or EBV status did not differ from that expected. The proportion of EBV is detected at low frequency in RA-related lymphomas in general (25, 26, 44), and although a role for EBV in some cases cannot be dismissed, it is unlikely to be of major importance.

Sjögren's Syndrome
Patients with Sjögren's (sicca) syndrome are at increased risk of developing NHL. Reported RRs range from about 4- to 40-fold and are higher for primary than for secondary disease (15, 23, 47-52). However, risk estimates are generally based on few lymphoma cases and 95% confidence intervals (95% CI) are therefore wide. In the hitherto largest cohort study of hospitalized patients (676 with primary and 709 with secondary Sjögren's syndrome; ref. 15), an NHL risk of 8.7 (95% CI, 4.3-15) was noted in association with the primary form (Table 1) and of 4.5 (95% CI, 1.5-11) for the secondary form. A recent large prospective cohort study, including 507 incident patients with primary Sjögren's syndrome (51), noted a 16-fold increased risk of lymphoma in patients fulfilling the diagnostic American-European Consensus Criteria (AECC; ref. 53) but found no risk increase in other sicca patients, suggesting a specificity of the association to strictly defined disease. In this study by Theander et al. (51), the risk was more pronounced with longer follow-up time (>10 years) among the AECC patients. Gender differences in risk have not been robustly evaluated due to the heavy predominance of female patients in Sjögren's syndrome (23, 48-52).

As in RA, markers of severe Sjögren's syndrome (e.g., parotid enlargement, hypocomplementemia, and palpable purpura) are associated with a more pronounced risk of NHL (51, 54, 55). In the only study that also evaluated CD4+ cytopenia and a low CD4+/CD8+ ratio, these factors were the strongest predictors of lymphoma development (51). Specific associations between immunosuppressive treatment and lymphoma risk in Sjögren's syndrome have been rarely reported (3).

With regard to lymphoma subtypes, case reports and case series have shown a striking occurrence of mucosa-associated lymphoid tissue (MALT) lymphomas, especially those located in the parotid gland, in Sjögren's syndrome (56, 57). However, more recent and systematic assessments indicate that the predominance of MALT lymphomas may not be as large as believed previously. In two well-defined cohorts of patients with Sjögren's syndrome, only 6 of 26 (58) and possibly 1 of 12 (51) NHLs were of MALT type. Instead, diffuse large B-cell lymphoma was the most common subtype in both studies (51, 58). Similarly, a recent case-control study (23) showed both a 28-fold increased risk of marginal zone lymphoma (including MALT lymphoma) and an 11-fold increased risk of diffuse large B-cell lymphoma. Conversely, in a series of 33 parotid MALT lymphoma cases, almost half (46%) of the patients had a history of Sjögren's syndrome (59). Thus, although the association between Sjögren's syndrome and parotid MALT lymphoma seems indisputable and biologically well defined (see below), there may also be an association with the more common diffuse large B-cell lymphoma subtype, although putative mechanisms behind such an association remain undefined. No increased occurrence of EBV-positive lymphomas has been reported in patients with Sjögren's syndrome (56). A role for the hepatitis C virus has been proposed but remains unclear (55, 59).

Systemic Lupus Erythematosus
In SLE, 10 of 14 separate studies, mostly of cohort but also of case-control design, reported a significantly 3- to 40-fold increased risk of NHL, and only 4 studies observed no, or only a suggested positive, association (23, 60-63). The largest studies by far, including a cohort of 5,700 patients with hospital discharge diagnoses of SLE (62) and an international multicenter cohort analysis encompassing the majority of previously published cohort studies (9,500 SLE patients in six countries; ref. 64), showed an overall 3- to 4-fold increased risk of NHL in association with SLE (Table 1). In the multicenter analysis, the excess risk persisted after 10 to 20 years of follow-up and was observed in both sexes (64). Disease-related risk factors responsible for this increase are unknown but under exploration (65). In cohort studies (66, 67) as well as case reports (68), few SLE patients who developed lymphoma were treated with immunosuppressive drugs, such as methotrexate, azathioprine, or cyclophosphamid. Hence, the role of these drugs in SLE-related lymphoma development does not seem to be pivotal. About lymphoma subtypes in SLE, all NHLs (n = 61) in a review of case reports (68) were of B-cell type, and HL and plasma cell disorders were also described (68). Two recent studies indicate that the proportion of diffuse large B-cell lymphomas is elevated among lymphomas complicating SLE (40-50%) compared with the expected fraction of all NHLs in the general population (25-30%; refs. 23, 65). The role of EBV in SLE-related lymphomas is uncertain (68).

Celiac Disease and Dermatitis Herpetiformis
Celiac disease and dermatitis herpetiformis, autoimmune disorders triggered by exposure to gliadin, occur at increased frequency in individuals with other autoimmune conditions (e.g., diabetes and RA). Highly increased lymphoma risks were reported in celiac disease decades ago (69, 70). However, older studies were based on small numbers (69) and patient series in referral clinics (70), resulting in imprecise risk estimation and possible selection of patients with unusual disease characteristics that may entail a higher risk of lymphoma. More recent large, population-based studies of mostly cohort but also case-control design described a lower, albeit still increased, risk of typically between 3- and 6-fold (Table 1; refs. 71-74). In the hitherto largest cohort study of 11,000 hospitalized patients (72), the 6-fold increase in risk (equal in both sexes) was restricted to patients diagnosed as adults and declined over successive calendar periods to a 3-fold excess risk during the 1990s. Whether the apparent discrepancies in risk between older and newer studies and the observed time trend relate to an increasing recognition of mild or silent celiac disease (presumably associated with a lower risk of NHL), a tendency toward earlier age at diagnosis or better management of patients is as yet unknown. Although attractive, the hypothesis that early total compliance to gluten-free diet therapy may protect against lymphomas in celiac disease is supported only by indirect evidence and studies, including very few lymphoma cases (70). With regard to dermatitis herpetiformis, the observed RR of lymphoma ranged from 2 to 10 in recent studies (Table 1; refs. 72, 75, 76).

Traditionally, celiac disease has been linked to an uncommon form of T-cell lymphoma in the small intestine, referred to as enteropathy-type T-cell lymphoma in the WHO classification (10). As with NHL subtypes in Sjögren's syndrome, however, recent and population-based studies indicate that other and more common lymphoma types, such as nonintestinal T-cell and B-cell NHL (71, 77), and perhaps diffuse large B-cell lymphomas in particular (23) also occur more often than expected. In dermatitis herpetiformis, occurrence of both B- and T-cell lymphomas has also been described (75, 78).

Hashimoto's Thyroiditis
Clinical cohort studies have reported a 3- to 4-fold increased risk of malignant lymphoma in association with chronic lymphocytic or Hashimoto's thyroiditis but with substantial imprecision (Table 1; refs. 79, 80). In the largest study, which included 5,500 female thyroiditis patients (80), all eight lymphomas observed were located in the thyroid gland. Conversely, in two series of patients with thyroid lymphoma, a clinical history of Hashimoto's thyroiditis was noted in about 40% of the patients (81), whereas >90% of the cases had histologic evidence of lymphocytic thyroiditis in thyroid tissue adjacent to the tumor (82). Thus, although Hashimoto's thyroiditis undoubtedly confers an increased risk of thyroid lymphoma, it is unclear whether the disease is also accompanied by an increased risk of lymphomas in other locations. Thyroid lymphomas are typically of the indolent MALT type, which occasionally transforms into more aggressive diffuse large B-cell lymphoma (82).

Polyomyositis and Dermatomyositis
Inflammatory myositis (primarily dermatomyositis and less so polymyositis) is associated with a 2- to 4-fold increased risk of NHL (Table 1; refs. 83, 84), although null results have also been reported (85). The increase in risk, however, is not specific for lymphoma but applies to malignancies overall and has been consistently observed to be highest around the time of the myositis diagnosis (84, 86, 87). In the largest investigation thus far, a pooled analysis of three Scandinavian cohorts, including 1,500 patients (84), there was no significant risk increase of NHL beyond the first year of follow-up (with five of eight NHLs diagnosed within the first year), and a considerable number of cancer cases also predated the myositis diagnosis. These observations suggest that inflammatory myositis may occur primarily as a paraneoplastic syndrome (3). Evidence is thus still scarce that the myositis disorders in themselves confer any elevated lymphoma risk. Furthermore, there is little to suggest that immunosuppressive therapy influences lymphoma occurrence in these patients (83, 88).

Inflammatory Bowel Disorders
In ulcerative colitis, most investigations favor no association with lymphoma risk (89-93). In the two largest and population-based cohort studies, including ~40,000 patients in total, the risk of lymphoma was close to unity [standardized incidence ratio (SIR), 1.1; 95% CI, 0.5-2.2 (92) and SIR, 1.0; 95% CI, 0.8-1.3 (93)]. In Crohn's disease, reports are somewhat less consistent. In a population-based cohort of ~3,000 Crohn's disease patients, a 2-fold excess risk of lymphoma was observed (SIR, 2.4; 95% CI, 1.2-5.0; ref. 91). A significant 2-fold risk increase was also reported for lymphoproliferative and myeloid malignancies in another twice as large cohort (94), but there was no separate assessment of lymphoma risk. Neither of these studies analyzed risk by duration of follow-up; therefore, the effect of possible initial misclassification cannot be evaluated. Several other reports are, however, consistent with no association (89, 92, 95, 96). The hitherto largest study, based on 20,000 patients, observed a 30% increased risk of lymphoma (SIR, 1.3; 95% CI, 1.0-1.6; ref. 93) excluding the first year of follow-up, but after 5 years the association approached unity. Thus, the result may reflect a true association as well as reversed causality or surveillance bias. We conclude that, to date, there is little to suggest a true excess risk of NHL, HL, chronic lymphocytic leukemia, or gastrointestinal lymphoma in ulcerative colitis, whereas an increased risk in subsets of patients with Crohn's disease cannot formally be excluded (23, 93). Nevertheless, any overall increase in NHL risk in Crohn's disease seems to be of much smaller magnitude than in, for example, RA and SLE.

Psoriasis and Spondylarthropathies
In psoriasis, several studies observed a statistically significant 2- to 8-fold increased risk of lymphoma (97-99), whereas others described no association (23, 100). Interestingly, practically all studies assessing risk by NHL subtype described a severalfold increased risk of T-cell lymphoma overall (22) or mycosis fungoides (101, 102). In the largest study by far, including ~150,000 patients with mild disease and 4,000 patients with severe psoriasis from the UK General Practice Research Database (103), there was a 4-fold excess risk of cutaneous T-cell lymphoma associated with mild disease and a >10-fold risk increase with severe disease but no significant association with other NHLs in either group. An increased risk of HL was also noted in both groups (RR, 1.4 and 3.2, respectively). Limitations of the investigation were the short follow-up time (median, 4-6 years) and the lack of evaluation of the effect of latency. Although evidence is indeed accumulating that psoriasis is associated with risk of cutaneous T-cell lymphomas in particular, possibly driving the association with increased risk of lymphoma overall in some studies, potential inflation of risk due to misclassification cannot be disregarded, as cutaneous T-cell lymphomas may initially mimic benign skin disorders, such as psoriasis (104). For other spondylarthropathies, data are scarce, with the exception of ankylosing spondylitis. In a cohort study of ~3,000 patients, an ~3-fold excess risk of lymphoma was reported based on the occurrence of 7 NHL cases (SIR, 2.8; 95% CI, 1.4-5.6), but latency was not evaluated (105). In addition, a 70% increased mortality due to NHL was observed in a historical cohort of 15,000 irradiated ankylosing spondylitis patients, but there was also a 30% increase in overall cancer mortality (106). In a recent registry-based case-control study, including 50,000 lymphoma patients and 93,000 matched population controls, there was no association between hospitalization for ankylosing spondylitis and risk of NHL or HL (risk of lymphoma overall, 1.0; 95% CI, 0.6-1.7; ref. 107). Thus, although a positive association between ankylosing spondylitis and lymphoma cannot be refuted, any association is likely to be of lower magnitude than that between, for example, RA and lymphoma risk.

Other Autoimmune Disorders
In systemic sclerosis, two cohort studies, including close to 1,000 hospitalized patients (108, 109), suggested a moderately increased risk of NHL or hematopoietic malignancy overall, whereas two other equally large clinical cohort studies observed no association (110, 111). However, each of these investigations was limited by small case numbers (about two cases of NHL or hematologic malignancies per study) and low precision (108-111). Hence, there is no conclusive evidence for an increased risk of NHL in systemic sclerosis. The only large-scale study of cancer risk in the rheumatic vasculitides reported a 4-fold excess lymphoma risk (SIR, 4.2; 95% CI, 1.8-8.3) in 1,000 patients hospitalized with Wegener's granulomatosis (112). However, there was no significantly increased risk beyond the first year of follow-up; thus, the positive association could be due to misclassification. In multiple sclerosis, studies have consistently shown no excess risk of lymphoma or hematopoietic malignancy (113-115). Associations between diabetes mellitus and malignant lymphomas have been described occasionally (116), but the overall picture is that of no association (117, 118). Two cohort studies with a total of 50,000 patients diagnosed with diabetes before age 30 years (predominantly type I/autoimmune diabetes) showed no excess risk of lymphoma (118, 119) but did not distinguish among lymphoma subtypes. In sarcoidosis, a chronic granulomatous condition that may involve an infectious origin and genetic susceptibility, case reports have highlighted a possible association with HL (120). One large cohort study based on ~9,000 patients found a 2-fold excess risk of lymphoma overall (SIR, 1.9; 95% CI, 1.3-2.7), but significantly increased risks of both NHL and HL were confined to the first 4 years of follow-up (121). As pulmonary or hilar lymphoma may mimic sarcoidosis, misclassification may have influenced the results. Two smaller cohorts with a total of 800 sarcoidosis patients and only one complicating lymphoma did not observe excess risk of lymphoma, although less than one case was expected (122, 123). In conclusion, an excess risk of lymphoma in sarcoidosis cannot be excluded, but current evidence is weak.

Nonautoimmune Inflammatory Conditions
Several infectious agents have been specifically linked to certain subtypes of lymphoma. These agents include the viruses HIV, EBV, human T-cell lymphotrophic virus-1, human herpes virus-8 (1), and hepatitis C virus (124) and the bacteria Helicobacter pylori (125), Borrelia burgdorferi (126), and most recently also Chlamydia psittaci (127) and Campylobacter jejunei (128). Most of these agents are believed to exert their lymphomagenic mechanisms primarily or partially through chronic immune stimulation (124, 126, 128-130). Infection-related systemic activation of the immune response, as observed in tuberculosis, malaria, herpes zoster, pneumonia, or pyelonephritis, was suggested as a risk factor for lymphoma in some studies (21, 60, 131, 132). Excess lymphoma risk in association with frequent use of antibiotics may reflect similar mechanisms (39). Chronic bronchitis is another inflammatory state that was associated with NHL risk in one study (133). However, asthma, similarly characterized by airway inflammation and hyperreactivity, seems to be inversely associated with NHL risk along with other allergic disorders (134). Thus, although a biological association is plausible, available data are yet insufficient to establish or exclude a general link between nonautoimmune inflammation and lymphoma risk.


   Common Mechanisms of Lymphomagenesis
Top
 Abstract
 Introduction
 Methodologic Issues
 Malignant Lymphomas
 Autoimmune/Inflammatory...
 Common Mechanisms of...
Clinical Aspects
 Conclusions
 References
 
The Role of Antigens
In normal B-cell development and differentiation, the development of antigen recognition through modification and selection of cell surface immunoglobulin receptors is of central importance. The processes of immunoglobulin variable-(diversity)-joining gene recombination and somatic hypermutation serve to increase receptor affinity for external or self-antigens (135). These genetic rearrangements also provide patterns of clonality that can be detected in immunoglobulin gene analyses. Reciprocal chromosomal translocations involving the immunoglobulin loci are a hallmark of most mature B-cell lymphomas and lead to dysregulated expression of proto-oncogenes important in cell proliferation, differentiation, and/or survival (e.g., c-myc, bcl-2, or bcl-6; ref. 10).

In Sjögren's syndrome, Hashimoto's thyroiditis, and celiac disease, mechanisms of development of specific lymphoma types in the affected organs are well documented. In Sjögren's syndrome and Hashimoto's thyroiditis, lymphomagenesis is attributed to local T-cell-dependent antigen-driven proliferation of B cells that eventually become monoclonal and develop into primarily low-grade MALT lymphoma (136, 137). Sustained antigenic drive during lymphoma transformation is implied by the presence of selected immunoglobulin variable gene mutations and clonal heterogeneity in the hypervariable regions within the tumor cells (136). Similarly, small intestinal T-cell lymphoma (i.e., enteropathy-type T cell) in celiac disease is suggested to develop from intraepithelial autoreactive T-cell infiltrates through polyclonal and monoclonal proliferations of cells with aberrant immune phenotypes (138). Other lines of evidence for the pathogenic importance of antigenic drive come from studies of H. pylori–associated gastric MALT lymphoma (139) and of hepatitis C virus–associated lymphoma (124), in which early lymphomatous lesions may regress on eradication of the antigen stimulus (124, 139). In chronic lymphocytic leukemia, molecular genetic studies indicate that malignant transformation could originate in B-cell precursors reactive to self-antigens (140).

With respect to the evolution of lymphomas without a clear connection to chronically inflamed sites, local antigen stimulation may still be of importance. In celiac disease, clonal lymphocytes are capable of disseminating into the bloodstream and to distant sites (138). This may also be true for transforming B cells in Sjögren's syndrome (141, 142). Nonmalignant B-cell subpopulations in the parotid gland of Sjögren patients have been shown to transform to overt lymphomas in extrasalivary sites, such as the lung and gastric ventricle (142, 143). In RA, ectopic germinal center formation in the synovium provides an ideal setting for continuous immune stimulation (144), and nonrandom use of immunoglobulin heavy chain genes and somatic mutation patterns indicative of antigen-driven selection have been observed in synovial cells of affected patients (145). In a recent case report, an aggressive RA-associated lymphoma was traced back to an antedating nodal oligoclonal lymphoproliferation (146). Interestingly, the neoplastic cells had significant sequence homology with B-cell lymphomas arising in Sjögren's syndrome and hepatitis C virus–associated mixed cryoglobulinemia, suggesting a possible common pathogenic pathway.

Other Mechanisms
It is conceivable that sustained antigen-driven B-cell proliferation may increase the risk of adverse genetic events, ultimately leading to the emergence of a neoplastic clone. The effect of such events could be enhanced by acquired resistance to apoptosis in autoimmune disorders (147). In RA and SLE, apoptotic resistance is increased and mediated by Bcl-2 expression, activation of nuclear factor-{kappa}B by inflammatory cytokines and growth factors, and abnormalities in the expression of B-cell activating factor (BAFF/BLyS, a member of the TNF superfamily; refs. 147, 148). Patients with Sjögren's syndrome, RA, and SLE have increased levels of BAFF in serum and synovial fluid (149), and BAFF levels in Sjögren's syndrome patients correlate with the level of disease-specific autoantibodies (149). B-cell activating factors have also been implicated in the growth and survival of B-cell malignancies (150). In one study, serum levels of BAFF were on average 3-fold higher in follicular lymphoma patients than in controls (151). Other cytokines of potential importance include (IL)-6 and IL-10 and TNF-{alpha}. IL-10 mediates autoantibody production and may function as an autocrine growth factor in B-cell lymphomas (152). Apart from being a key inflammatory mediator in RA and other inflammatory diseases, TNF is also a growth factor for lymphoma. Recently, in a pooled analysis within a large lymphoma study consortium (InterLymph; ref. 153), genetic variation in the TNF-{alpha} and IL-10 genes was associated with an up to 2-fold increased risk of diffuse large B-cell lymphoma, the subtype particularly associated with several autoimmune disorders in other studies (23, 25, 51, 65). Interestingly, variation in TNF-{alpha} and related receptor genes may also increase susceptibility to SLE and Sjögren's syndrome (154). In another study, IL-10 and IL-4 polymorphisms were modestly but significantly associated with NHL risk (155), leading the authors to speculate that abnormalities in the T helper (TH) cell type 2 immune response enhance lymphomagenesis. Autoimmune disorders are also associated with alterations in the TH cell response, although in various ways. RA, sarcoidosis, and psoriasis are characterized by accumulation of TH1 lymphocytes, SLE by a TH2 response (156), and Sjögren's syndrome by high serum levels of both TH1 and TH2 cytokines (157). Therefore, an altered TH1/TH2 balance does not in itself explain why some but not other autoimmune disorders are associated with increased lymphoma occurrence.


   Clinical Aspects
Top
 Abstract
 Introduction
 Methodologic Issues
 Malignant Lymphomas
 Autoimmune/Inflammatory...
 Common Mechanisms of...
 Clinical Aspects
Conclusions
 References
 
Little is known about whether the clinical behavior of lymphomas complicating autoimmune disorders is different from that of lymphomas in general. In one study of 33 RA-associated NHLs (predominantly diffuse large B-cell NHL), median survival time from lymphoma diagnosis was as short as 6 months (45), indicating a worse outcome than for NHL or diffuse large B-cell lymphoma in general (158). However, in another study of 65 RA lymphoma cases and 1,500 non-RA lymphoma controls (159), RA was inversely associated with death from lymphoma or its treatment (hazard ratio, 0.60; 95% CI, 0.37-0.98) but positively associated with death from other causes. These disparate results may relate in part to advances in lymphoma diagnostics and treatment over time, as the larger study was more recent. A possible misclassification of cause of death as unrelated to lymphoma in the latter study could also have concealed a worse outcome of RA lymphomas. Thus, this question remains to be further investigated. Accordingly, it is also unclear whether these patients should be treated differently following lymphoma diagnosis. For obvious reasons, treatment with monoclonal anti-CD20 antibodies (rituximab), which has become part of standard therapy for patients with CD20+ lymphomas (160) and is currently being introduced for the treatment of several autoimmune disorders, is an option that may strike two birds with one stone.


   Conclusions
Top
 Abstract
 Introduction
 Methodologic Issues
 Malignant Lymphomas
 Autoimmune/Inflammatory...
 Common Mechanisms of...
 Clinical Aspects
 Conclusions
References
 
The association between several autoimmune and inflammatory disorders and risk of malignant lymphomas is now well established. In addition, evidence is accumulating, primarily from studies of RA and Sjögren's syndrome, that the increased lymphoma risk in these patient groups is mainly due to high inflammatory activity and severity of disease, rather than treatment, in a subgroup of patients. Here, two distinctions are particularly important to keep in mind. First, there is the distinction between the average risk in a group of patients and the risk confined to a particular subgroup, as exemplified by the indication that a minority of RA patients with severe disease may account for the majority of the doubled overall lymphoma burden in RA. Second, there is the distinction between relative and absolute risks. Even a highly increased RR, such as the 50-fold excess risk of enteropathy-type T-cell in celiac disease, translates to a very small absolute risk expressed in terms of the percentage of all patients with celiac disease. On the other hand, extrapolations from available risk data suggest that high-risk subsets of patients, such as those with severe RA, may face a 10% or greater life-time risk of developing lymphoma.

An important challenge over the coming years will be to define algorithms for the identification of autoimmune/inflammatory patients at high risk of lymphoma, to evaluate their pretreatment lymphoma risk profile, and to quantify this risk in absolute terms. Another important issue will be to assess whether the new immunomodulatory treatments increase, decrease, or do not affect the short- and long-term clinical occurrence and course of malignant lymphomas in patients otherwise prone to lymphoma development. Additional research is also needed to further explore biological mechanisms and understand the interplay between genetic susceptibility to lymphoma, such as common variation in IL genes outlined above, and inflammatory activity. With respect to "sporadic" lymphomas, it is important to understand whether also frequent short periods of common but nonautoimmune inflammation or inflammation in response to infection confers an increase in risk, perhaps primarily in genetically susceptible individuals. If so, lymphomagenesis in autoimmune inflammation may serve as a model for a much larger proportion of patients.


   Acknowledgments
 
We thank Profs. Hans-Olov Adami and Lars Klareskog for valuable comments on this review, Associate Prof. Richard Rosenqvist-Brandell for specific comments on biological mechanisms, and Dr. Ellen Chang for language revision.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 4/17/06; revised 8/23/06; accepted 9/ 6/06.


   References
Top
 Abstract
 Introduction
 Methodologic Issues
 Malignant Lymphomas
 Autoimmune/Inflammatory...
 Common Mechanisms of...
 Clinical Aspects
 Conclusions
 References
 

  1. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004;23:6524–34.[CrossRef][Medline]
  2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533–43.[CrossRef][Medline]
  3. Leandro MJ, Isenberg DA. Rheumatic diseases and malignancy—is there an association? Scand J Rheumatol 2001;30:185–8.[CrossRef][Medline]
  4. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337–44.[Abstract/Free Full Text]
  5. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151–8.[CrossRef][Medline]
  6. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275–85.[Abstract/Free Full Text]
  7. Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 2004;16:254–61.[CrossRef][Medline]
  8. Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy and autoimmunity. Curr Opin Rheumatol 2006;18:129–34.[Medline]
  9. Ehrenfeld M, Abu-Shakra M, Buskila D, Shoenfeld Y. The dual association between lymphoma and autoimmunity. Blood Cells Mol Dis 2001;27:750–6.[CrossRef][Medline]
  10. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics of tumours of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
  11. Cartwright RA, Watkins G. Epidemiology of Hodgkin's disease: a review. Hematol Oncol 2004;22:11–26.[CrossRef][Medline]
  12. Hartge P, Devesa SS. Quantification of the impact of known risk factors on time trends in non-Hodgkin's lymphoma incidence. Cancer Res 1992;52:5566–9s.
  13. Hakulinen T, Isomaki H, Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med 1985;78:29–32.[Medline]
  14. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753–7.[CrossRef]
  15. Kauppi M, Pukkala E, Isomaki H. Elevated incidence of hematologic malignancies in patients with Sjogren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 1997;8:201–4.[CrossRef][Medline]
  16. Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497–502.[CrossRef][Medline]
  17. Ekstrom K, Hjalgrim H, Brandt L, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003;48:963–70.[CrossRef][Medline]
  18. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50:1740–51.[CrossRef][Medline]
  19. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414–20.[Abstract/Free Full Text]
  20. Franklin J, Lunt M, Bunn D, Symmons DP, Silman AJ. Incidence of lymphoma in a large primary-care derived cohort of inflammatory polyarthritis. Ann Rheum Dis 2006;65:617–22.[Abstract/Free Full Text]
  21. Tavani A, La Vecchia C, Franceschi S, Serraino D, Carbone A. Medical history and risk of Hodgkin's and non-Hodgkin's lymphomas. Eur J Cancer Prev 2000;9:59–64.[CrossRef][Medline]
  22. Zhang Y, Holford TR, Leaderer B, et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 2004;15:419–28.[CrossRef][Medline]
  23. Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006;98:51–60.[Abstract/Free Full Text]
  24. Gridley G, Klippel JH, Hoover RN, Fraumeni JF, Jr. Incidence of cancer among men with the Felty syndrome. Ann Intern Med 1994;120:35–9.[Abstract/Free Full Text]
  25. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317:180–1.[Free Full Text]
  26. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692–701.[CrossRef][Medline]
  27. Matteson EL, Hickey AR, Maguire L, Tilson HH, Urowitz MB. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee. J Rheumatol 1991;18:809–14.[Medline]
  28. Jones M, Symmons D, Finn J, Wolfe F. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 1996;35:738–45.[Abstract/Free Full Text]
  29. Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999;26:1705–14.[Medline]
  30. Wolfe F. Inflammatory activity, but not methotrexate or prednisone use predicts non-Hodgkin's lymphoma in rheumatoid arthritis: a 25-year study of 1,767 RA patients [abstract]. Arthritis Rheum 1998;41Suppl 9:188.[CrossRef][Medline]
  31. Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996;14:1943–9.[Abstract/Free Full Text]
  32. Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002;99:3909–15.[Abstract/Free Full Text]
  33. Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993;328:1317–21.[Free Full Text]
  34. Kato I, Koenig KL, Shore RE, et al. Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin's lymphoma (NHL) (United States). Cancer Causes Control 2002;13:965–74.[CrossRef][Medline]
  35. Cerhan JR, Anderson KE, Janney CA, Vachon CM, Witzig TE, Habermann TM. Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer 2003;106:784–8.[CrossRef][Medline]
  36. Sorensen HT, Mellemkjaer L, Nielsen GL, Baron JA, Olsen JH, Karagas MR. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 2004;96:709–11.[Abstract/Free Full Text]
  37. Sorensen HT, Friis S, Norgard B, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003;88:1687–92.[CrossRef][Medline]
  38. Beiderbeck AB, Holly EA, Sturkenboom MC, Coebergh JW, Stricker BH, Leufkens HG. Prescription medications associated with a decreased risk of non-Hodgkin's lymphoma. Am J Epidemiol 2003;157:510–6.[Abstract/Free Full Text]
  39. Chang ET, Smedby KE, Hjalgrim H, et al. Medication use and risk of non-Hodgkin's lymphoma. Am J Epidemiol 2005;162:965–74.[Abstract/Free Full Text]
  40. Beiderbeck AB, Holly EA, Sturkenboom MC, Coebergh JW, Stricker BH, Leufkens HG. No increased risk of non-Hodgkin's lymphoma with steroids, estrogens, and psychotropics (Netherlands). Cancer Causes Control 2003;14:639–44.[CrossRef][Medline]
  41. Askling J, Klareskog L, Hjalgrim H, Baecklund E, Bjorkholm M, Ekbom A. Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis. Ann Rheum Dis 2005;64:1765–8.[Abstract/Free Full Text]
  42. Biogen. Package literature for Amevive. Cambridge (MA): Biogen; 2003.
  43. Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699–703.[Abstract/Free Full Text]
  44. Kamel OW, Holly EA, van de Rijn M, Lele C, Sah A. A population based, case control study of non-Hodgkin's lymphoma in patients with rheumatoid arthritis. J Rheumatol 1999;26:1676–80.[Medline]
  45. Baecklund E, Sundstrom C, Ekbom A, et al. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum 2003;48:1543–50.[CrossRef][Medline]
  46. Glaser SL, Swartz WG. Time trends in Hodgkin's disease incidence. The role of diagnostic accuracy. Cancer 1990;66:2196–204.[CrossRef][Medline]
  47. Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978;89:888–92.[Abstract/Free Full Text]
  48. Valesini G, Priori R, Bavoillot D, et al. Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjogren's syndrome. J Rheumatol 1997;24:2376–80.[Medline]
  49. Davidson BK, Kelly CA, Griffiths ID. Primary Sjogren's syndrome in the north east of England: a long-term follow-up study. Rheumatology (Oxford) 1999;38:245–53.[Medline]
  50. Pertovaara M, Pukkala E, Laippala P, Miettinen A, Pasternack A. A longitudinal cohort study of Finnish patients with primary Sjogren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 2001;60:467–72.[Abstract/Free Full Text]
  51. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjogren's syndrome A cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006;65:796–803.[Abstract/Free Full Text]
  52. Engels EA, Cerhan JR, Linet MS, et al. Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin's lymphoma: a case-control study. Am J Epidemiol 2005;162:1153–61.[Abstract/Free Full Text]
  53. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554–8.[Abstract/Free Full Text]
  54. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 2002;46:741–7.[CrossRef][Medline]
  55. Ramos-Casals M, Brito-Zeron P, Yague J, et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2005;44:89–94.[CrossRef][Medline]
  56. Royer B, Cazals-Hatem D, Sibilia J, et al. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 1997;90:766–75.[Abstract/Free Full Text]
  57. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum 1999;42:1765–72.[CrossRef][Medline]
  58. Tonami H, Matoba M, Kuginuki Y, et al. Clinical and imaging findings of lymphoma in patients with Sjogren syndrome. J Comput Assist Tomogr 2003;27:517–24.[CrossRef][Medline]
  59. Ambrosetti A, Zanotti R, Pattaro C, et al. Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection. Br J Haematol 2004;126:43–9.[CrossRef][Medline]
  60. Vineis P, Crosignani P, Sacerdote C, et al. Haematopoietic cancer and medical history: a multicentre case control study. J Epidemiol Community Health 2000;54:431–6.[Abstract/Free Full Text]
  61. Bernatsky S, Clarke A, Ramsey-Goldman R. Malignancy and systemic lupus erythematosus. Curr Rheumatol Rep 2002;4:351–8.[Medline]
  62. Bjornadal L, Lofstrom B, Yin L, Lundberg IE, Ekbom A. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 2002;31:66–71.[CrossRef][Medline]
  63. Ragnarsson O, Grondal G, Steinsson K. Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus. Lupus 2003;12:687–91.[Abstract/Free Full Text]
  64. Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005;52:1481–90.[CrossRef][Medline]
  65. Bernatsky S, Ramsey-Goldman R, Rajan R, et al. Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis 2005;64:1507–9.[Abstract/Free Full Text]
  66. Ramsey-Goldman R, Mattai SA, Schilling E, et al. Increased risk of malignancy in patients with systemic lupus erythematosus. J Investig Med 1998;46:217–22.[Medline]
  67. Cibere J, Sibley J, Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus 2001;10:394–400.[Abstract/Free Full Text]
  68. Xu Y, Wiernik PH. Systemic lupus erythematosus and B-cell hematologic neoplasm. Lupus 2001;10:841–50.[Abstract/Free Full Text]
  69. Selby WS, Gallagher ND. Malignancy in a 19-year experience of adult celiac disease. Dig Dis Sci 1979;24:684–8.[CrossRef][Medline]
  70. Holmes GK, Prior P, Lane MR, Pope D, Allan RN. Malignancy in coeliac disease-effect of a gluten free diet. Gut 1989;30:333–8.[Abstract/Free Full Text]
  71. Catassi C, Fabiani E, Corrao G, et al. Risk of non-Hodgkin lymphoma in celiac disease. JAMA 2002;287:1413–9.[Abstract/Free Full Text]
  72. Askling J, Linet M, Gridley G, Halstensen TS, Ekstrom K, Ekbom A. Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology 2002;123:1428–35.[CrossRef][Medline]
  73. Green PH, Fleischauer AT, Bhagat G, Goyal R, Jabri B, Neugut AI. Risk of malignancy in patients with celiac disease. Am J Med 2003;115:191–5.[CrossRef][Medline]
  74. West J, Logan RF, Smith CJ, Hubbard RB, Card TR. Malignancy and mortality in people with coeliac disease: population based cohort study. BMJ 2004;329:716–9.[Abstract/Free Full Text]
  75. Sigurgeirsson B, Agnarsson BA, Lindelof B. Risk of lymphoma in patients with dermatitis herpetiformis. BMJ 1994;308:13–5.[Abstract/Free Full Text]
  76. Collin P, Pukkala E, Reunala T. Malignancy and survival in dermatitis herpetiformis: a comparison with coeliac disease. Gut 1996;38:528–30.[Abstract/Free Full Text]
  77. Smedby KE, Akerman M, Hildebrand H, Glimelius B, Ekbom A, Askling J. Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma. Gut 2005;54:54–9.[Abstract/Free Full Text]
  78. Hervonen K, Vornanen M, Kautiainen H, Collin P, Reunala T. Lymphoma in patients with dermatitis herpetiformis and their first-degree relatives. Br J Dermatol 2005;152:82–6.[CrossRef][Medline]
  79. Holm LE, Blomgren H, Lowhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med 1985;312:601–4.[Abstract]
  80. Kato I, Tajima K, Suchi T, et al. Chronic thyroiditis as a risk factor of B-cell lymphoma in the thyroid gland. Jpn J Cancer Res 1985;76:1085–90.
  81. Thieblemont C, Mayer A, Dumontet C, et al. Primary thyroid lymphoma is a heterogeneous disease. J Clin Endocrinol Metab 2002;87:105–11.[Abstract/Free Full Text]
  82. Derringer GA, Thompson LD, Frommelt RA, Bijwaard KE, Heffess CS, Abbondanzo SL. Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol 2000;24:623–39.[CrossRef][Medline]
  83. Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992;326:363–7.[Abstract]
  84. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96–100.[CrossRef][Medline]
  85. Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 2001;85:41–5.[CrossRef][Medline]
  86. Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994;21:1855–9.[Medline]
  87. Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001;134:1087–95.[Abstract/Free Full Text]
  88. Airio A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 1995;22:1300–3.[Medline]
  89. Ekbom A, Helmick C, Zack M, Adami HO. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991;67:2015–9.[CrossRef][Medline]
  90. Mellemkjaer L, Olsen JH, Frisch M, Johansen C, Gridley G, McLaughlin JK. Cancer in patients with ulcerative colitis. Int J Cancer 1995;60:330–3.[Medline]
  91. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001;91:854–62.[CrossRef][Medline]
  92. Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001;121:1080–7.[CrossRef][Medline]
  93. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005;54:617–22.[Abstract/Free Full Text]
  94. Arseneau KO, Stukenborg GJ, Connors AF, Jr., Cominelli F. The incidence of lymphoid and myeloid malignancies among hospitalized Crohn's disease patients. Inflamm Bowel Dis 2001;7:106–12.[CrossRef][Medline]
  95. Persson PG, Karlen P, Bernell O, et al. Crohn's disease and cancer: a population-based cohort study. Gastroenterology 1994;107:1675–9.[Medline]
  96. Mellemkjaer L, Johansen C, Gridley G, Linet MS, Kjaer SK, Olsen JH. Crohn's disease and cancer risk (Denmark). Cancer Causes Control 2000;11:145–50.[CrossRef][Medline]
  97. Hannuksela-Svahn A, Pukkala E, Laara E, Poikolainen K, Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000;114:587–90.[CrossRef][Medline]
  98. Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch Dermatol 2001;137:778–83.[Abstract/Free Full Text]
  99. Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003;139:1425–9.[Abstract/Free Full Text]
  100. Lindelof B, Eklund G, Liden S, Stern RS. The prevalence of malignant tumors in patients with psoriasis. J Am Acad Dermatol 1990;22:1056–60.[Medline]
  101. Frentz G, Olsen JH. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 1999;140:237–42.[CrossRef][Medline]
  102. Boffetta P, Gridley G, Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001;117:1531–7.[CrossRef][Medline]
  103. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006;126:2194–201. Epub 2006 Jun 1.[CrossRef][Medline]
  104. Zackheim HS, McCalmont TH. Mycosis fungoides: the great imitator. J Am Acad Dermatol 2002;47:914–8.[CrossRef][Medline]
  105. Shibata A, Zhao S, Makuch RW, Wentworth C, Veith J, Wallis W. Lymphoma risk in ankylosing spondylitis patients is greater than that observed in the general population [abstract]. Ann Rheum Dis 2004;63Suppl 1:98.[Abstract/Free Full Text]
  106. Weiss HA, Darby SC, Doll R. Cancer mortality following X-ray treatment for ankylosing spondylitis. Int J Cancer 1994;59:327–38.[Medline]
  107. Askling J, Klareskog L, Fored M, Blomqvist P, Feltelius N. Risk for malignant lymphoma in ankylosing spondylitis. a nationwide Swedish case-control study. Ann Rheum Dis 2006;65:1184–7.[Abstract/Free Full Text]
  108. Rosenthal AK, McLaughlin JK, Linet MS, Persson I. Scleroderma and malignancy: an epidemiological study. Ann Rheum Dis 1993;52:531–3.[Abstract/Free Full Text]
  109. Rosenthal AK, McLaughlin JK, Gridley G, Nyren O. Incidence of cancer among patients with systemic sclerosis. Cancer 1995;76:910–4.[CrossRef][Medline]
  110. Hill CL, Nguyen AM, Roder D, Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003;62:728–31.[Abstract/Free Full Text]
  111. Chatterjee S, Dombi GW, Severson RK, Mayes MD. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 2005;52:2415–24.[CrossRef][Medline]
  112. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 2002;100:82–5.[CrossRef][Medline]
  113. Midgard R, Glattre E, Gronning M, Riise T, Edland A, Nyland H. Multiple sclerosis and cancer in Norway. A retrospective cohort study. Acta Neurol Scand 1996;93:411–5.[Medline]
  114. Sumelahti ML, Pukkala E, Hakama M. Cancer incidence in multiple sclerosis: a 35-year follow-up. Neuroepidemiology 2004;23:224–7.[CrossRef][Medline]
  115. Moller H, Kneller RW, Boice JD, Jr., Olsen JH. Cancer incidence following hospitalization for multiple sclerosis in Denmark. Acta Neurol Scand 1991;84:214–20.[Medline]
  116. Cerhan JR, Wallace RB, Folsom AR, et al. Medical history risk factors for non-Hodgkin's lymphoma in older women. J Natl Cancer Inst 1997;89:314–8.[Abstract]
  117. Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997;89:1360–5.[Abstract/Free Full Text]
  118. Zendehdel K, Nyren O, Ostenson CG, Adami HO, Ekbom A, Ye W. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 2003;95:1797–800.[Abstract/Free Full Text]
  119. Swerdlow AJ, Laing SP, Qiao Z, et al. Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer 2005;92:2070–5.[CrossRef][Medline]
  120. Simsek S, van Leuven F, Bronsveld W, Ooms GH, Groeneveld AB, de Graaff CS. Unusual association of Hodgkin's disease and sarcoidosis. Neth J Med 2002;60:438–40.[Medline]
  121. Askling J, Grunewald J, Eklund A, Hillerdal G, Ekbom A. Increased risk for cancer following sarcoidosis. Am J Respir Crit Care Med 1999;160:1668–72.[Abstract/Free Full Text]
  122. Seersholm N, Vestbo J, Viskum K. Risk of malignant neoplasms in patients with pulmonary sarcoidosis. Thorax 1997;52:892–4.[Abstract]
  123. Romer FK, Hommelgaard P, Schou G. Sarcoidosis and cancer revisited: a long-term follow-up study of 555 Danish sarcoidosis patients. Eur Respir J 1998;12:906–12.[Abstract]
  124. Libra M, Gasparotto D, Gloghini A, Navolanic PM, De Re V, Carbone A. Hepatitis C virus (HCV) I hepatitis C virus (HCV) infection and lymphoproliferative disorders. Front Biosci 2005;10:2460–71.[Medline]
  125. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991;338:1175–6.[CrossRef][Medline]
  126. Goodlad JR, Davidson MM, Hollowood K, et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the highlands of Scotland. Am J Surg Pathol 2000;24:1279–85.[Medline]
  127. Ferreri AJ, Guidoboni M, Ponzoni M, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004;96:586–94.[Abstract/Free Full Text]
  128. Lecuit M, Abachin E, Martin A, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004;350:239–48.[Abstract/Free Full Text]
  129. Hussell T, Isaacson PG, Crabtree JE, Spencer J. Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol 1996;178:122–7.[CrossRef][Medline]
  130. Aboulafia DM, Pantanowitz L, Dezube BJ. AIDS-related non-Hodgkin lymphoma: still a problem in the era of HAART. AIDS Read 2004;14:605–17.[Medline]
  131. La Vecchia C, Negri E, Franceschi S. Medical history and the risk of non-Hodgkin's lymphomas. Cancer Epidemiol Biomarkers Prev 1992;1:533–6.[Abstract/Free Full Text]
  132. Askling J, Ekbom A. Risk of non-Hodgkin's lymphoma following tuberculosis. Br J Cancer 2001;84:113–5.[CrossRef][Medline]
  133. Franceschi S, Serraino D, Bidoli E, et al. The epidemiology of non-Hodgkin's lymphoma in the north-east of Italy: a hospital-based case-control study. Leuk Res 1989;13:465–72.[CrossRef][Medline]
  134. Grulich AE, Vajdic CM, Kaldor JM, et al. Birth order, atopy, and risk of non-Hodgkin lymphoma. J Natl Cancer Inst 2005;97:587–94.[Abstract/Free Full Text]
  135. Mackay IR, Rose NR. Autoimmunity and lymphoma: tribulations of B cells. Nat Immunol 2001;2:793–5.[CrossRef][Medline]
  136. Morse HC, III, Kearney JF, Isaacson PG, Carroll M, Fredrickson TN, Jaffe ES. Cells of the marginal zone-origins, function, and neoplasia. Leuk Res 2001;25:169–78.[CrossRef][Medline]
  137. Yamamoto K. Pathogenesis of Sjogren's syndrome. Autoimmun Rev 2003;2:13–8.[CrossRef][Medline]
  138. Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000;356:203–8.[CrossRef][Medline]
  139. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575–7.[CrossRef][Medline]
  140. Herve M, Xu K, Ng YS, et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 2005;115:1636–43.[CrossRef][Medline]
  141. Mariette X. Lymphomas in patients with Sjogren's syndrome: review of the literature and physiopathologic hypothesis. Leuk Lymphoma 1999;33:93–9.[Medline]
  142. Gasparotto D, De Vita S, De Re V, et al. Extrasalivary lymphoma development in Sjogren's syndrome: clonal evolution from parotid gland lymphoproliferation and role of local triggering. Arthritis Rheum 2003;48:3181–6.[CrossRef][Medline]
  143. De Vita S, Boiocchi M, Sorrentino D, et al. Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjogren's syndrome. Arthritis Rheum 1997;40:318–31.[Medline]
  144. Weyand CM, Seyler TM, Goronzy JJ. B cells in rheumatoid synovitis. Arthritis Res Ther 2005;7 Suppl 3:S9–12.[Medline]
  145. Kim HJ, Berek C. B cells in rheumatoid arthritis. Arthritis Res 2000;2:126–31.[CrossRef][Medline]
  146. Quartuccio L, De Re V, Fabris M, et al. Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization. Haematologica 2006;91:691–4.[Abstract/Free Full Text]
  147. Eguchi K. Apoptosis in autoimmune diseases. Intern Med 2001;40:275–84.[Medline]
  148. Mackay F, Sierro F, Grey ST, Gordon TP. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 2005;8:243–65.[Medline]
  149. Szodoray P, Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjogren's syndrome. Scand J Immunol 2005;62:421–8.[CrossRef][Medline]
  150. Jelinek DF, Darce JR. Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors. Curr Dir Autoimmun 2005;8:266–88.[Medline]
  151. Briones J, Timmerman JM, Hilbert DM, Levy R. BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp Hematol 2002;30:135–41.[CrossRef][Medline]
  152. Emilie D, Zou W, Fior R, et al. Production and roles of IL-6, IL-10, and IL-13 in B-lymphocyte malignancies and in B-lymphocyte hyperactivity of HIV infection and autoimmunity. Methods 1997;11:133–42.[CrossRef][Medline]
  153. Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006;7:27–38.[CrossRef][Medline]
  154. Hajeer AH, Hutchinson IV. TNF-{alpha} gene polymorphism: clinical and biological implications. Microsc Res Tech 2000;50:216–28.[CrossRef][Medline]
  155. Lan Q, Zheng T, Rothman N, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006;107:4101–8.[Abstract/Free Full Text]
  156. Kalsi JK, Grossman J, Kim J, et al. Peptides from antibodies to DNA elicit cytokine release from peripheral blood mononuclear cells of patients with systemic lupus erythematosus: relation of cytokine pattern to disease duration. Lupus 2004;13:490–500.[Abstract/Free Full Text]
  157. Garcic-Carrasco M, Font J, Filella X, et al. Circulating levels of Th1/Th2 cytokines in patients with primary Sjogren's syndrome: correlation with clinical and immunological features. Clin Exp Rheumatol 2001;19:411–5.[Medline]
  158. Evans LS, Hancock BW. Non-Hodgkin lymphoma. Lancet 2003;362:139–46.[CrossRef][Medline]
  159. Mikuls TR, Endo JO, Puumala SE, et al. Prospective study of survival outcomes in non-Hodgkin's lymphoma patients with rheumatoid arthritis. J Clin Oncol 2006;24:1597–602.[Abstract/Free Full Text]
  160. Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004;55:477–503.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 LupusHome page
P Miljic, B Bonaci-Nikolic, N Colovic, T Terzic, and M Colovic
Antiribosomal-P protein antibodies in a patient with systemic lupus erythematosus and non-Hodgkin's lymphoma: more than coincidental finding?
Lupus, January 1, 2009; 18(1): 81 - 85.
[Abstract] [PDF]

Home page
 BloodHome page
L. M. Morton, S. S. Wang, W. Cozen, M. S. Linet, N. Chatterjee, S. Davis, R. K. Severson, J. S. Colt, M. A. Vasef, N. Rothman, et al.
Etiologic heterogeneity among non-Hodgkin lymphoma subtypes
Blood, December 15, 2008; 112(13): 5150 - 5160.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
J. Koshiol, G. Gridley, E. A. Engels, M. L. McMaster, and O. Landgren
Chronic Immune Stimulation and Subsequent Waldenstrom Macroglobulinemia
Arch Intern Med, September 22, 2008; 168(17): 1903 - 1909.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Ishii, S. Ito, Y. Kondo, H. Tsuboi, M. Mamura, D. Goto, I. Matsumoto, A. Tsutsumi, T. Sumida, Y. Okoshi, et al.
Intravascular Large B-Cell Lymphoma With Acute Abdomen As a Presenting Symptom in a Patient With Systemic Lupus Erythematosus
J. Clin. Oncol., March 20, 2008; 26(9): 1553 - 1555.
[Full Text] [PDF]

Home page
 GutHome page
S. B Hanauer
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Gut, September 1, 2007; 56(9): 1181 - 1183.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
S. S. Wang, W. Cozen, J. R. Cerhan, J. S. Colt, L. M. Morton, E. A. Engels, S. Davis, R. K. Severson, N. Rothman, S. J. Chanock, et al.
Immune Mechanisms in Non-Hodgkin Lymphoma: Joint Effects of the TNF G308A and IL10 T3575A Polymorphisms with Non-Hodgkin Lymphoma Risk Factors
Cancer Res., May 15, 2007; 67(10): 5042 - 5054.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T. Mikuls
The treatment of lymphoma complicating autoimmune disease: two birds with one stone?
Ann. Onc., April 1, 2007; 18(4): 615 - 618.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smedby, K. E.
Right arrow Articles by Askling, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smedby, K. E.
Right arrow Articles by Askling, J.
Related Collections
Right arrow Epidemiology and Prevention
Right arrow Epidemiology and Prevention: Genetics and Biomarkers

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online